Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations

Author： Bloomer Jackie  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.6, 2013-06, pp. : 737-751

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug-Drug Interactions via Mechanism-Based Cytochrome P450 Inactivation: Points to Consider for Risk Assessment from In Vitro Data and Clinical Pharmacologic Evaluation

By  

Current Drug Metabolism, Vol. 8, Iss. 5, 2007-06 ,pp. : 449-462

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m‐hydroxymexiletine

By  

Pharmacology Research & Perspectives, Vol. 3, Iss. 5, 2015-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug-Drug Interaction Prediction Assessment

By Zhou Jihao  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 4, 2009-07 ,pp. : 641-657

Taylor & Francis Ltd

Access to resources Recommend Favorite

What is the true risk of a pharmacokinetic drug–drug interaction?

By Fuhr Uwe  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 10, 2007-10 ,pp. : 897-899

Springer Publishing Company

Access to resources Recommend Favorite

Risk Assessment in Drug Development: Autoimmunity

By Hastings Kenneth  

Journal of Toxicology and Environmental Health, Vol. 69, Iss. 9, 2006-05 ,pp. : 893-898

Taylor & Francis Ltd

Access to resources Recommend Favorite